- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC
May 15th 2024, 6:03pm
ESMO Breast Cancer Virtual Meeting
First-line atezolizumab plus sacituzumab govitecan led to responses in PD-L1–positive locally advanced or metastatic triple-negative breast cancer.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
May 6th 2024, 9:50pm
American Urological Association Annual Meeting
No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
May 6th 2024, 7:57pm
American Urological Association Annual Meeting
Angela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
May 6th 2024, 7:13pm
American Urological Association Annual Meeting
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
May 6th 2024, 3:11am
Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.
TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer
May 5th 2024, 10:41pm
American Urological Association Annual Meeting
TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.
Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy
May 5th 2024, 10:03pm
American Urological Association Annual Meeting
Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC
May 5th 2024, 9:53pm
American Urological Association Annual Meeting
Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).
Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC
May 5th 2024, 8:30pm
American Urological Association Annual Meeting
Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.
UGN-102 With/Without TURBT Produces Similar DOR and DFS in Newly Diagnosed and Recurrent NMIBC
May 5th 2024, 2:21pm
American Urological Association Annual Meeting
UGN-102 with/without TURBT displayed meaningful and similar DFS and DOR rates in newly diagnosed and recurrent low-grade intermediate-risk NMIBC.
Dr Wang on the Role of Active Surveillance in Patients With Renal Masses
May 4th 2024, 10:07pm
American Urological Association Annual Meeting
Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.
Dr Meeks on Harnessing Innovation in Bladder Cancer
May 4th 2024, 8:09pm
American Urological Association Annual Meeting
Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.
PSMA-PET Plus Multi-Parametric MRI Aids Detection of Clinically Significant Prostate Cancer
May 4th 2024, 2:30pm
American Urological Association Annual Meeting
18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.
Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC
May 4th 2024, 1:00pm
American Urological Association Annual Meeting
Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.
Dr Shore on the Importance of a Multidisciplinary Team in Urologic Oncology
May 3rd 2024, 11:26pm
Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.
Apalutamide/ADT Demonstrates 100% Biochemical RFS Rate in High-Risk Prostate Cancer
May 3rd 2024, 10:45pm
American Urological Association Annual Meeting
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.
Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
May 3rd 2024, 10:20pm
American Urological Association Annual Meeting
Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.
18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer
May 3rd 2024, 10:05pm
American Urological Association Annual Meeting
18F-PSMA-1007 PET/CT generated superior locoregional staging results vs multiparametric MRI in patients with prostate cancer.
Extended Lymphadenectomy Shows No DFS, OS Benefit During Radical Cystectomy in Urothelial Cancer
May 3rd 2024, 10:02pm
American Urological Association Annual Meeting
Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.
TAR-200 Leads to Durable Responses in Bacillus Calmette–Guérin-Unresponsive NMIBC
May 3rd 2024, 8:48pm
American Urological Association Annual Meeting
TAR-200 displayed a high complete response rate in Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer.